Literature DB >> 65920

Electroimmunoassay of alpha-2-opsonic protein during reticuloendothelial blockade.

F Blumenstock, P Weber, T M Saba, R Laffin.   

Abstract

Physiological regulation of reticuloendothelial (RE) phagocytic activity by a plasma opsonic factor has been documented. In the recent study, serum levels of this alpha-2-opsonic protein in rats during colloid-induced RE blockade were measured utilizing an electroimmunoassay (Rocket immunoelectrophoresis) with monospecific antiserum to the purified alpha-2-glycoprotein. RE blockade was produced by the intravenous injection of the gelatinized "RE-test-lipid emulsion" at a dose of 50 mg/100 g body wt. The opsonic activity of serum at various intervals during colloid-induced RE blockade as measured by tissue slice bioassay manifested a high correlation (r = 0.98) with the serum opsonic protein concentration as measured by the electroimmunoassay. During RE blockade (30 min), there was a rapid depletion of the opsonic alpha-2-glycoprotein to 20% of the initial preinjection levels. Serum concentration of this glycoprotein remained low for at least 2-3 h after which time its concentration progressively increased with approximation of normal values by 6 h postblockade. Opsonic protein concentration at 24 h postinjection were significantly (P less than 0.05) elevated above controls. Thus, colloid-induced RE blockade is associated with the removal of this glycoprotein from the serum and recovery from RE blockade is accompanied by a restoration of opsonin levels. The electroimmunoassay can provide a sensitive technique to monitor this humoral factor known to exert a physiological control on the RE system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 65920     DOI: 10.1152/ajpregu.1977.232.3.R80

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  The role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase.

Authors:  D K Meijer; H B Scholtens; M J Hardonk
Journal:  Pharm Weekbl Sci       Date:  1982-06-25

Review 2.  Fibronectin: a review of its structure and biological activity.

Authors:  E Pearlstein; L I Gold; A Garcia-Pardo
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

3.  Phagocytosis-promoting activity of avian plasma and fibroblastic cell surface fibronectins.

Authors:  D Marquette; J Molnar; K Yamada; D Schlesinger; S Darby; P Van Alten
Journal:  Mol Cell Biochem       Date:  1981-05-26       Impact factor: 3.396

4.  Mechanism of acute depletion of plasma fibronectin following thermal injury in rats. Appearance of a gelatinlike ligand in plasma.

Authors:  D C Deno; M H McCafferty; T M Saba; F A Blumenstock
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Lung vascular permeability after reversal of fibronectin deficiency in septic sheep. Correlation with patient studies.

Authors:  T M Saba; G D Niehaus; W A Scovill; F A Blumenstock; J C Newell; J Holman; S R Powers
Journal:  Ann Surg       Date:  1983-11       Impact factor: 12.969

6.  Reversal of fibronectin and opsonic deficiency in patients. A controlled study.

Authors:  T M Saba; F A Blumenstock; D M Shah; J E Kaplan; E Cho; W Scovill; H Stratton; J Newell; M Gottlieb; N Sedransk
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

7.  Reticuloendothelial clearance of blood-borne particulates: relevance to experimental lung microembolization and vascular injury.

Authors:  G D Niehaus; P R Schumacker; T M Saba
Journal:  Ann Surg       Date:  1980-04       Impact factor: 12.969

8.  Comparative influence of blood-borne nonbacterial particles and Staphylococcus aureus on fibronectin, complement and immunoglobulin.

Authors:  M H McCafferty; T M Saba
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

9.  Fibronectin levels during intraperitoneal inflammation.

Authors:  P S Richards; T M Saba
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.